Legend Capital, the venture and growth capital arm of China’s Legend Holdings Ltd, has co-led an RMB2 billion ($293 million) investment in Chinese Diagnostics Medical Corporation by joining China Renaissance’s healthcare fund, China Money Network reported.

Other investors including Matrix Partners, Ping An Ventures, High Light Capital, Zhongjin Kangrui Healthcare Industrial Fund, and Shanghai Free Trade Zone Equity Fund (FTZ Fund) also participated in the round.

Incorporated in 1999, Chinese Diagnostics Medical Corporation specializes in the design and development of diagnostic testing reagents. The company has more than 20 medical inspection centers across China. It also has an R&D team of about 30.